[HTML][HTML] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
…, MW Schuster, D Irwin, EA Stadtmauer… - New England journal …, 2005 - Mass Medical Soc
Background This study compared bortezomib with high-dose dexamethasone in patients
with relapsed multiple myeloma who had received one to three previous therapies. Methods …
with relapsed multiple myeloma who had received one to three previous therapies. Methods …
CRISPR-engineered T cells in patients with refractory cancer
EA Stadtmauer, JA Fraietta, MM Davis, AD Cohen… - Science, 2020 - science.org
INTRODUCTION Most cancers are recognized and attacked by the immune system but can
progress owing to tumor-mediated immunosuppression and immune evasion mechanisms. …
progress owing to tumor-mediated immunosuppression and immune evasion mechanisms. …
[HTML][HTML] Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast …
EA Stadtmauer, A O'Neill, LJ Goldstein… - … England Journal of …, 2000 - Mass Medical Soc
Background We conducted a randomized trial in which we compared high-dose chemotherapy
plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-…
plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-…
[HTML][HTML] Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
…, M Wang, A Belch, EA Stadtmauer… - … England Journal of …, 2007 - Mass Medical Soc
Background Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but
has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. …
has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma. …
[HTML][HTML] Lenalidomide after stem-cell transplantation for multiple myeloma
…, PG Richardson, S Giralt, EA Stadtmauer… - … England Journal of …, 2012 - Mass Medical Soc
Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …
time to disease progression after autologous hematopoietic stem-cell transplantation in …
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
GP Linette, EA Stadtmauer, MV Maus… - Blood, The Journal …, 2013 - ashpublications.org
An obstacle to cancer immunotherapy has been that the affinity of T-cell receptors (TCRs) for
antigens expressed in tumors is generally low. We initiated clinical testing of engineered T …
antigens expressed in tumors is generally low. We initiated clinical testing of engineered T …
[PDF][PDF] Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers, RA Larson, EA Stadtmauer, E Estey… - Journal of Clinical …, 2001 - Citeseer
Purpose: Three open-label, multicenter trials were conducted to evaluate the efficacy and
safety of singleagent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, …
safety of singleagent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, …
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
JF DiPersio, EA Stadtmauer… - Blood, The Journal …, 2009 - ashpublications.org
This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated
the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in …
the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in …
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl… - Nature medicine, 2015 - nature.com
Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Here
we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells …
we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells …
[PDF][PDF] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
…, JP Leonard, S Lonial, EA Stadtmauer… - Journal of clinical …, 2006 - academia.edu
… Stadtmauer, Owen A. O’Connor, Hongliang Shi, Anthony L. Boral, and André Goy …
Stadtmauer, Owen A. O’Connor, Anthony L. Boral, André Goy Final approval of manuscript …
Stadtmauer, Owen A. O’Connor, Anthony L. Boral, André Goy Final approval of manuscript …